keyword
https://read.qxmd.com/read/37244845/systematic-review-and-cost-effectiveness-analysis-of-the-treatment-of-post-stroke-spasticity-with-abobotulinumtoxina-compared-to-physiotherapy
#21
JOURNAL ARTICLE
María Errea Rodríguez, María Fernández, Juan Del Llano, Roberto Nuño-Solinís
OBJECTIVE: Post-stroke spasticity (PSS) is a common complication in stroke survivors, causing severe burden to patients living with it. The aim of this review was to conduct a cost-effectiveness analysis (CEA) of the treatment of post-stroke spasticity, in adults, with abobotulinumtoxinA compared to the best supportive care, based on results from a systematic literature review. Given that abobotulinumtoxinA (aboBoNT-A) is always accompanied by the best supportive care treatment, the CEA compared aboBoNT-A plus the best supportive care with the best supportive care alone...
2023: Farmacia Hospitalaria
https://read.qxmd.com/read/37235349/replacement-of-the-mouse-ld-50-assay-for-determination-of-the-potency-of-abobotulinumtoxina-with-a-cell-based-method-in-both-powder-and-liquid-formulations
#22
JOURNAL ARTICLE
Elena Fonfria, Elizabeth Marks, Lisa-Marie Foulkes, Rebecca Schofield, Daniel Higazi, Sam Coward, Alistair Kippen
Botulinum neurotoxins (BoNTs) are important therapeutic agents. The in vivo median lethal dose (LD50 ) assay has been commonly used to measure the potency of BoNT commercial preparations. As an alternative, we developed cell-based assays for abobotulinumtoxinA in both powder (Dysport® , Azzalure® ) and liquid (Alluzience® ) formulations using the in vitro BoCell® system. The assays demonstrated linearity over 50-130% of the expected relative potency, with a correlation coefficient of 0.98...
April 29, 2023: Toxins
https://read.qxmd.com/read/37205243/conversion-to-abobotulinumtoxina-increases-waning-time-and-efficacy-for-cervical-dystonia
#23
JOURNAL ARTICLE
Olivia Samotus, Mandar Jog
BACKGROUND: Symptom re-emergence before re-injection negatively impacts cervical dystonia (CD) patients receiving botulinum toxin type A (BoNT-A) therapy. Longer waning time is associated with abobotulinumtoxinA (abo-BoNT-A) as compared to onabotulinumtoxinA (ona-BoNT-A)/incobotulinumtoxinA (inco-BoNT-A) formulations. OBJECTIVES: To compare waning time and treatment outcomes when chronically injected CD patients experiencing early waning despite being optimized on BoNT-A (ona-BoNT-A/inco-BoNT-A) were converted to abo-BoNT-A...
May 2023: Movement Disorders Clinical Practice
https://read.qxmd.com/read/37096009/the-safety-of-botulinum-neurotoxin-type-a-s-intraarticular-application-in-experimental-animals
#24
JOURNAL ARTICLE
Ana Dugonjić Okroša, Victor Ricardo Manuel Muñoz-Lora, Ivica Matak, Lidija Bach-Rojecky, Mikhail Kalinichev, Zdravko Lacković
In vivo studies of botulinum neurotoxin type A (BoNT-A) enabled characterization of its activity in the nociceptive sensory system separate from its preferred action in motor and autonomic nerve terminals. However, in the recent rodent studies of arthritic pain which employed high intra-articular (i.a.) doses (expressed as a total number of units (U) per animal or U/kg), possible systemic effects have not been conclusively excluded. Herein we assessed the effect of two pharmaceutical preparations, abobotulinumtoxinA (aboBoNT-A, 10, 20, and 40 U/kg corresponding to 0...
June 2023: Toxicon: X
https://read.qxmd.com/read/37060926/video-enhanced-visual-analysis-of-hemiparetic-gait-muscle-selection-a-pilot-study
#25
JOURNAL ARTICLE
Alberto Esquenazi
This paper summarizes the use of video enhanced visual analysis (VEVA) as a muscle selection assistance method for abnormal foot postures in adults with upper motor neuron syndrome (UMNS) treated with botulinum neurotoxin (BoNT-A) in a real-world setting. This pilot study used a prospective treatment study design with persons in an outpatient, rehabilitation hospital. Participants had acquired brain injury (ABI) of >6-month duration who had a spastic ankle foot deformity amenable to treatment with botulinum toxin A and able to independently ambulate a minimum of 10 m...
June 1, 2023: Toxicon: Official Journal of the International Society on Toxinology
https://read.qxmd.com/read/36951993/correction-efficacy-and-safety-of-abobotulinumtoxina-for-the-treatment-of-glabellar-lines-in-chinese-patients-a-pivotal-phase-3-randomized-double-blind-and-open-label-phase-study
#26
Yan Wu, Fang Fang, Wei Lai, Chengxin Li, Li Li, Quanzhong Liu, Jianyun Lu, Xiaowen Pang, Jiaming Sun, Xiaofeng Shi, Philippe Picaut, Inna Prygova, Bill Andriopoulos, Qiuning Sun
No abstract text is available yet for this article.
March 23, 2023: Aesthetic Plastic Surgery
https://read.qxmd.com/read/36828465/the-relationship-between-pain-and-spasticity-and-tell-tale-signs-of-pain-in-children-with-cerebral-palsy
#27
JOURNAL ARTICLE
Christian Wong
Pain and quality of life are closely interrelated in children with cerebral palsy (CCP). Even though 67% of CCP experience pain, it is overlooked and untreated. In this study, our purpose was two-fold: first, to examine the relationship between pain and spasticity by evaluating the effects of AbobotulinumtoxinA/Dysport (BoNT), and second, to describe the symptoms and location of pain in CCP. The subjects were 22 CCP in at least moderate pain. They were evaluated for spasticity by the modified Ashworth and Tardieu scale and for pain by the r-FLACC and the pediatric pain profile...
February 13, 2023: Toxins
https://read.qxmd.com/read/36828397/cosmetic-treatment-using-botulinum-toxin-in-the-oral-and-maxillofacial-area-a-narrative-review-of-esthetic-techniques
#28
REVIEW
Sung Ok Hong
Botulinum toxin (BoNT) is an anaerobic rod-shaped-neurotoxin produced by Clostridium botulinum, that has both therapeutic and lethal applications. BoNT injection is the most popular cosmetic procedure worldwide with various applications. Patients with dynamic wrinkles in areas such as the glabella, forehead, peri-orbital lines, nasal rhytides, and perioral rhytides are indicated. Excessive contraction of muscles or hyperactivity of specific muscles such as bulky masseters, cobble stone chins, gummy smiles, asymmetric smiles, and depressed mouth corners can achieve esthetic results by targeting the precise muscles...
January 17, 2023: Toxins
https://read.qxmd.com/read/36804286/exploring-the-relationship-between-clinical-presentation-in-hallux-valgus-and-response-to-abobotulinumtoxina-treatment
#29
JOURNAL ARTICLE
Babak Baravarian, Lawrence A DiDomenico, Magali Volteau, David G Armstrong, Robert Silva
The relationship between pain/disability and angular deviation of the hallux valgus (HV), and the impact of orthotic use, laterality, and pain variability on treatment outcomes remain unclear. This was explored in post hoc analyses of a placebo-controlled trial of abobotulinumtoxinA (aboBoNT-A; Dysport®) for HV-associated pain (NCT03569098). The primary endpoint was not met in this study (change from baseline Numeric Pain Rating Scale [NPRS] score vs placebo at week 8); however, there was a greater reduction from baseline in mean NPRS score at week 12 with aboBoNT-A 500U versus placebo (p = ...
January 19, 2023: Journal of Foot and Ankle Surgery
https://read.qxmd.com/read/36647624/efficacy-of-abobotulinumtoxina-versus-onabotulinumtoxina-for-the-treatment-of-refractory-neurogenic-detrusor-overactivity-a-systematic-review-and-indirect-treatment-comparison
#30
JOURNAL ARTICLE
Francisco Cruz, Natalya Danchenko, Kyle Fahrbach, Andreas Freitag, Jialu Tarpey, John Whalen
AIMS: To compare the efficacy and safety of abobotulinumtoxinA1 (aboBoNT-A) and onabotulinumtoxinA2 (onaBoNT-A) for the treatment of refractory neurogenic detrusor overactivity (NDO), using indirect treatment comparison (ITC). MATERIALS AND METHODS: A systematic literature review was used to identify randomized controlled trials (RCTs) that evaluated botulinum toxin type A for the treatment of refractory NDO. Treatments were compared using a Bucher ITC approach...
January 16, 2023: Journal of Medical Economics
https://read.qxmd.com/read/36585269/effects-of-botulinum-toxin-injection-on-reducing-myogenic-artifacts-during-video-eeg-monitoring-a-longitudinal-study
#31
JOURNAL ARTICLE
Babak Ghelichnia, Pargol Balali, Ghasem Farahmand, Mahdi Shafiee Sabet, Somaye Feizi, Bahareh Pourghaz, Melika Jameie, Abbas Tafakhori
Medically refractory seizures affect one-third of patients with epilepsy (PwE), for whom epilepsy surgery is considered. Video electroencephalography (vEEG) monitoring is a fundamental tool for pre-operative seizure localization. Facial and cranial myogenic artifacts can obscure vEEG findings, thus interfering with seizure localization. Studies have shown the beneficial effects of botulinum toxin type A (BTX-A) injection into cranial muscles for reducing myogenic artifacts. This longitudinal study aimed to assess the effects of BTX-A injection on these artifacts...
December 2022: Neurodiagnostic Journal
https://read.qxmd.com/read/36536093/efficacy-and-safety-of-abobotulinumtoxina-for-the-treatment-of-glabellar-lines-in-chinese-patients-a-pivotal-phase-3-randomized-double-blind-and-open-label-phase-study
#32
JOURNAL ARTICLE
Yan Wu, Fang Fang, Wei Lai, Chengxin Li, Li Li, Quanzhong Liu, Jianyun Lu, Xiaowen Pang, Jiaming Sun, Xiaofeng Shi, Philippe Picaut, Inna Prygova, Bill Andriopoulos, Qiuning Sun
BACKGROUND: Various botulinumtoxinA formulations are approved for glabellar lines treatment worldwide, including abobotulinumtoxinA (Dysport® ). OBJECTIVES: Assess abobotulinumtoxinA superiority versus placebo and non-inferiority versus active comparator (onabotulinumtoxinA; Botox® ), for the treatment of Chinese patients with moderate/severe glabellar lines. METHODS: Phase 3, randomized study (NCT02450526) comprising a double-blind (cycle 1) phase and an open-label (cycles 2-5) phase...
December 19, 2022: Aesthetic Plastic Surgery
https://read.qxmd.com/read/36513684/intraoperative-abobotulinumtoxina-alleviates-pain-after-surgery-and-improves-general-wellness-in-a-translational-animal-model
#33
JOURNAL ARTICLE
Sylvie Cornet, Denis Carré, Lorenzo Limana, David Castel, Sigal Meilin, Ron Horne, Laurent Pons, Steven Evans, Stephane Lezmi, Mikhail Kalinichev
Pain after surgery remains a significant healthcare challenge. Here, abobotulinumtoxinA (aboBoNT-A, DYSPORT) was assessed in a post-surgical pain model in pigs. Full-skin-muscle incision and retraction surgery on the lower back was followed by intradermal injections of either aboBoNT-A (100, 200, or 400 U/pig), vehicle (saline), or wound infiltration of extended-release bupivacaine. We assessed mechanical sensitivity, distress behaviors, latency to approach the investigator, and wound inflammation/healing for 5-6 days post-surgery...
December 13, 2022: Scientific Reports
https://read.qxmd.com/read/36422983/post-hoc-subgroup-analysis-of-the-bcause-study-assessing-the-effect-of-abobotulinumtoxina-on-post-stroke-shoulder-pain-in-adults
#34
JOURNAL ARTICLE
Marcelo Riberto, João Amaury Frances, Regina Chueire, Ana Cristina Ferreira Garcia Amorim, Denise Xerez, Tae Mo Chung, Lucia Helena Costa Mercuri, Sérgio Lianza, Eduardo Carvalho de Melo Rocha, Pascal Maisonobe, Thais Cuperman-Pohl, Patricia Khan
Botulinum toxin type A is approved for the focal treatment of spasticity; however, the effectiveness of abobotulinumtoxinA (aboBoNT-A) in patients with shoulder pain who have set reduced pain as a treatment goal is understudied. In addition, some patients encounter delays in accessing treatment programs; therefore, the suitability of aboBoNT-A for pain reduction in this population requires investigation. These factors were assessed in aboBoNT-A-naive Brazilian patients in a post hoc analysis of data from BCause, an observational, multicenter, prospective study (NCT02390206)...
November 20, 2022: Toxins
https://read.qxmd.com/read/36406303/treatment-of-segmental-continuous-hypertrophic-myokymia-of-the-limb-with-botulinum-a-toxin
#35
Muhammad Ismail Khalid Yousaf, Mohammad Ravi Ghani, Talita D'Aguiar Rosa, Victoria Holiday, Martin Brown, Peter Hedera
Myokymia is defined as fluctuating hyperexcitability of muscle fibers caused by repetitive spontaneous contraction of motor units. Myokymia is generally benign with self-resolution, although symptomatic treatment with benzodiazepines, anticonvulsants, and muscle relaxants can be used. Botulinum toxins can also be utilized, although they are mostly used for symptomatic facial myokymia. Here, we report two patients who developed continuous myokymia, resulting in secondary hypertrophy, stiffness, and discomfort in the affected muscles...
2022: SAGE Open Medical Case Reports
https://read.qxmd.com/read/36405048/sensory-symptoms-associated-with-aesthetic-botulinum-toxin-a-treatments
#36
JOURNAL ARTICLE
Niamh Corduff
UNLABELLED: A retrospective review of patients who switched from onabotulinumtoxinA (onaA) and/or abobotulinumtoxinA (aboA) to incobotulinumtoxinA (incoA) found anecdotal reports of differences in "feel," including a "lighter" feel or treatment-associated tightness. We surveyed the frequency of these sensations as an initial proof of concept of toxin proprioception among our patients who switched toxins. METHODS: Seventy-nine patients who had past facial aesthetic treatments with more than one botulinum toxin A (BoNT/A) formulation completed a questionnaire on their experience of treatment-associated sensations, including stiffness or a frozen feeling...
November 2022: Plastic and Reconstructive Surgery. Global Open
https://read.qxmd.com/read/36355984/abobotulinumtoxina-doses-in-upper-and-lower-limb-spasticity-a-systematic-literature-review
#37
REVIEW
Alexis Schnitzler, Clément Dince, Andreas Freitag, Ike Iheanacho, Kyle Fahrbach, Louis Lavoie, Jean-Yves Loze, Anne Forestier, David Gasq
Disabling limb spasticity can result from stroke, traumatic brain injury or other disorders causing upper motor neuron lesions such as multiple sclerosis. Clinical studies have shown that abobotulinumtoxinA (AboBoNT-A) therapy reduces upper and lower limb spasticity in adults. However, physicians may administer potentially inadequate doses, given the lack of consensus on adjusting dose according to muscle volume, the wide dose ranges in the summary of product characteristics or cited in the published literature, and/or the high quantity of toxin available for injection...
October 26, 2022: Toxins
https://read.qxmd.com/read/36335048/pain-reduction-with-abobotulinumtoxina-for-the-treatment-of-hallux-valgus-in-adult-participants-results-of-a-randomized-and-placebo-controlled-phase-2-trial
#38
JOURNAL ARTICLE
David G Armstrong, Lawrence A DiDomenico, Babak Baravarian, Selene G Parekh, Magali Volteau, Robert Silva
AbobotulinumtoxinA (aboBoNT-A, Dysport® [Ipsen, Paris, France]) inhibits acetylcholine release at the neuromuscular junction and may modulate pain signaling in hallux valgus (HV). This randomized study (NCT03569098) included a double-blind phase (aboBoNT-A 300U, 500U or placebo injections into forefoot muscles) and an open-label aboBoNT-A treatment period in participants with an HV diagnosis and no HV surgery. The primary endpoint was change from baseline in numeric pain rating scale (NPRS) score at week 8...
July 12, 2022: Journal of Foot and Ankle Surgery
https://read.qxmd.com/read/36321799/abobotulinumtoxina-is-effective-in-patients-with-urinary-incontinence-due-to-neurogenic-detrusor-overactivity-regardless-of-spinal-cord-injury-or-multiple-sclerosis-etiology-pooled-analysis-of-two-phase-iii-randomized-studies-content1-and-content2
#39
RANDOMIZED CONTROLLED TRIAL
Pierre Denys, Juan Carlos Castaño Botero, Ricardo Luis Vita Nunes, Barton Wachs, Cristiano Mendes Gomes, Grigory Krivoborodov, Le Mai Tu, Giulio Del-Popolo, Catherine Thompson, Claire Vilain, Magali Volteau, Michael Kennelly
BACKGROUND: Neurogenic detrusor overactivity incontinence (NDOI) is often inadequately managed with oral therapy. OBJECTIVE: To assess efficacy and safety of abobotulinumtoxinA (aboBoNT-A; Dysport®; Ipsen Ltd.) according to etiology of NDOI. DESIGN, SETTING, AND PARTICIPANTS: Two phase III, randomized, double-blind studies (CONTENT1 [NCT02660138] conducted in Asia, Europe and North America; CONTENT2 [NCT02660359] conducted in the Americas, Asia, Europe and Oceania) both included patients with spinal cord injury (SCI) or multiple sclerosis (MS), with inadequately managed NDOI, regularly performing clean intermittent catheterization (CIC)...
January 2023: Neurourology and Urodynamics
https://read.qxmd.com/read/36306168/goal-attainment-after-treatment-with-abobotulinumtoxina-and-a-tailored-home-therapy-programme-in-children-with-upper-limb-spasticity-descriptive-exploratory-analysis-of-a-large-randomized-controlled-study
#40
JOURNAL ARTICLE
Jorge Carranza-Del Río, Nigar Dursun, Cigdem Cekmece, Marcin Bonikowski, Weronika Pyrzanowska, Edward Dabrowski, Ann Tilton, Joyce Oleszek, Magali Volteau, Simon Page, Angela Shierk, Mauricio Delgado
OBJECTIVE: This exploratory analysis of a large, randomized, double-blind study (NCT02106351) describes the effect of treatment with abobotulinumtoxinA followed by a tailored home exercises therapy programme in enabling children with upper limb spasticity due to cerebral palsy to achieve their functional goals using goal attainment scaling (GAS). METHODS: Children with cerebral palsy and spasticity in ≥ 1 upper limb received up to 4 injection cycles of abobotulinumtoxinA (2 U/kg (cycle 1 only), 8U/kg and 16U/kg) into the elbow and wrist flexors and other upper limb muscles selected to support individual treatment goals...
October 28, 2022: Journal of Rehabilitation Medicine
keyword
keyword
9458
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.